ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1804

Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, B-Lymphocyte, genomics, Systemic lupus erythematosus (SLE), T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will never develop clinical illness. Incomplete lupus (ILE) patients exhibit some clinical symptoms, while most never progress to SLE. It is unknown what triggers ANA+ healthy individuals to progress to clinical illness. Alterations in B and T cell receptor repertoires (BCR/TCR) of patients with different autoimmune diseases have been found to affect immune tolerance. This study investigates changes in immune receptors repertoires in preclinical SLE.

Methods: We selected 64 individuals of African and European American ancestry (ANA-, ANA+ healthy controls, ILE, SLE). Single cell transcriptomics, VDJ-clone and surface protein profiles for PBMCs were developed using Single Cell Immune Profiling scRNA-Seq platform (10x Genomics) along with TotalSeq Human Universal cocktail (Biolegend) to assess B/T cell clonal expansion, identify VDJ gene usage during preclinical autoimmunity development and find transcriptionally similar clonotypes. BCR/TCR data were analyzed with Python packages Scirpy and Dandelion.

Results: We found higher number of expanded clonotypes in ILE and SLE individuals, particularly of Memory B cells, ABCs and Plasma cells (Fig.1A). It appears clonal expansion is present mostly in individuals of European American ancestry. The largest clonotypes are present across those three populations (Fig.1B). Additionally, we observed larger CDR3 lengths in ABCs and Plasma cells (Fig.1C). B cell receptor repertoire appear to have an overlap in ANA- and ANA+ healthy individuals; however not between disease groups (Fig.1D). Clonotypes with highest modularity score; indicating transcriptional similarity, are restricted to Memory B cells, ABCs and Plasma cell populations (Fig.1E). Differential expression analysis of B cells in the two top scoring clonotypes indicates involvement of the following genes: IGKV1-5, IGLV7-46, IGHV1-69, IGHG1, IGHV1-69D, as well as S100A8, IFI30. One of the most abundant V genes (IGKV2D) is mostly related to ANA+ individuals, while IGLV4-3 and IGKV2D-30 across SLE. We found cytotoxic T cells have largest fraction of expanded clonotypes with further increase in ANA+ individuals (Fig.1F-H). However, we haven’t observed differences in expansion by ancestry. Clonotypes with a high modularity score, consisting of cells with similar molecular phenotype, are located mostly within CD8+ cytotoxic T cells and CD4+ Th1-like populations and are associated with higher expression of TXNIP, TMSB4X, HLA, GZMB (Fig.1I-J).

Conclusion: In conclusion, we found specific clonal characteristics affecting preclinical autoimmunity development that suggest involvement of lymphocyte population expansion.

Supporting image 1

Fig1. Evaluation of B/T cell receptor repertoires across preclinical disease development. A. Bar plot showing clonal expansion of B cell subpopulations. B. Bar plot with largest B cell clones by cell type. C. Spectratype plot with the length distribution of CDR3 regions by B cell type. D. A heatmap showing abundance of B cell clonotypes in each disease group and their similarities. E. Scatterplot visualizing clonotype modularity representing molecular phenotype with the associated FDR values and UMAP plots of associated B cell populations with clonotypes that are most similar transcriptionally. F. Clone size visualized on T cell UMAP plot with yellow indicating largest clonotypes. G. Bar plot showing clonal expansion of T cell subpopulations. H. Bar plot with largest T cell clones by cell type. I. Scatterplot visualizing transcriptionally similar T cell clonotypes with associated FDR values and corresponding UMAP plots of T cell populations with most similar clonotypes. J. Differential expression analysis of genes related to defined similar T cell clonotypes.


Disclosures: A. Bylinska: None; M. Smith: None; R. Lu: None; B. Jones: None; C. Guthridge: None; M. Marlin: None; C. Wright: None; S. Macwana: None; W. DeJager: None; M. Beel: None; C. Lessard: Johnson and Johnson Innovative Medicine, 2, 5, Johnson and Johnson Sjögren's Disease Advisory Board, 1; C. Arriens: AstraZeneca, 1, 5, 6, Aurinia, 1, 6, Bristol-Myers Squibb(BMS), 1, 5, Cabaletta, 1, GlaxoSmithKlein(GSK), 1, Kezar, 1, Synthekine, 1, UCB, 1; J. Merrill: AbbVie, 1, 2, Alexion, 1, 2, Alumis, 1, 2, Amgen, 1, 2, AstraZeneca, 1, 2, 5, Aurinia, 1, 2, Bristol Myers Squibb, 1, 2, 5, EMD Serono, 1, 2, Genentech, 1, 2, Gilead, 1, 2, GlaxoSmithKline, 1, 2, 5, Kezar, 1, 2, Lilly, 1, 2, Merck, 1, 2, Pfizer, 1, 2, Provention, 1, 2, Remegen, 1, 2, Sanofi, 1, 2, Takeda, 1, 2, UCB, 1, 2, Zenas, 1, 2; J. James: GlaxoSmithKlein(GSK), 1, Progentec Diagnostics, Inc., 5, 10; J. Guthridge: AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5.

To cite this abstract in AMA style:

Bylinska A, Smith M, Lu R, Jones B, Guthridge C, Marlin M, Wright C, Macwana S, DeJager W, Beel M, Lessard C, Arriens C, Merrill J, James J, Guthridge J. Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/investigating-adaptive-immune-receptor-repertoires-by-deep-immune-cell-phenotyping-in-preclinical-autoimmunity-development/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-adaptive-immune-receptor-repertoires-by-deep-immune-cell-phenotyping-in-preclinical-autoimmunity-development/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology